Abstract
Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.
Original language | English |
---|---|
Pages (from-to) | 103-108 |
Number of pages | 6 |
Journal | Journal of Neuro-Oncology |
Volume | 7 |
Issue number | 1 |
DOIs | |
Publication status | Published - May 1989 |
Keywords
- brain tumor metabolism
- Lonidamine
- malignant glioma
ASJC Scopus subject areas
- Neuroscience(all)
- Oncology
- Clinical Neurology
- Cancer Research